Controlling and conquering incurable metastatic cancer by targeting the major tumor-driving K-RAS/SIAH pathway activation to stratify patients, identify resistant tumor clones, quantify therapy efficacy, forecast tumor relapse, and predict patient survival in the neoadjuvant settings
Meeting Abstract
